Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$10.12
-$0.03(-0.47%)
At close: 4:00 PM EST
$10.12
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$6.62 - $15.35
Previous CloseN/A
Volume124.17K
Average Volume (3M)1.08M
Market Cap
$1.16B
Enterprise Value$720.06
Total Cash (Recent Filing)$71.54M
Total Debt (Recent Filing)$87.53M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 06, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume824,556
30 Day Avg. Volume1,077,840
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside147.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$49.80M
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayThe royalty purchase agreement and accompanying equity commitments materially extend near-term liquidity and removed earlier Perceptive debt, reshaping the capital structure. This reduces near-term refinancing risk and provides durable funding runway to advance clinical programs toward commercialization over several years.
Very High Gross MarginsSustained ~94% gross margins indicate a high-value, scalable revenue base typical of proprietary biologics/gene therapies. High product-level margins give the company structural leverage to cover SG&A and R&D as revenues scale, supporting long-term path to profitability if commercial uptake grows.
Operating Cash Flow Turning PositiveThe shift to positive operating cash flow (~$8M TTM) signals improving cash generation from core operations, reducing dependency on equity/debt in the near term. Consistent OCF is a durable indicator of operational progress and supports reinvestment into clinical programs and commercialization activities.
Bears Say
Large Recurring Net LossesSignificant trailing losses (~$121M) versus modest revenue mean the business still needs to materially scale revenue or cut structural costs to reach profitability. Ongoing operating losses increase reliance on external funding and leave outcomes sensitive to execution and commercial adoption over multiple quarters.
Negative Stockholders' EquityA negative equity position (~-$58M) reduces financial flexibility and can constrain capital markets access or increase the cost of new financing. It represents an enduring balance-sheet weakness that can amplify dilution or covenant risk until cumulative losses are restored by profits or fresh capital.
Contingent Nature Of Additional Funding TranchesWhile the royalty facility provides material optional funding, much of it is milestone-conditional. Future tranche availability depends on clinical and regulatory progress, creating structural execution risk: if trials or approvals falter, expected funding may not materialize and the company may face renewed liquidity pressure.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was $6.62 and its highest was $15.35 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is $1.16B.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on May 14, 2026. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.036.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.33.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (147.04% Upside)
$25.00 (147.04% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 144.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$25.00
▲(147.04% Upside)
Technical Analysis
Ownership Overview
15.56% Insiders
1.86% Mutual Funds
0.48% Other Institutional Investors
76.31% Public Companies and
Individual Investors